Nexthera Capital’s ProQR Therapeutics PRQR Stock Holding History

Nexthera Capital’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-52,875	Closed	-$1.02M	–	40
2018 Q3	$1.02M	Buy	+52,875	New	+$562K	0.2%	47

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Nexthera Capital's PRQR Position: Q4 2018 in Review

Nexthera Capital sold out of ProQR Therapeutics (PRQR) in Q4 2018, closing a stake of 52,875 shares — an estimated $1.02M sold.

Nexthera Capital first reported a position in PRQR in Q3 2018 and held it in 1 quarter. The position peaked at $1.02M in Q3 2018. 57 funds tracked by Wall St. Rank hold PRQR as of Q4 2018.

Nexthera Capital reported no remaining ProQR Therapeutics position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 52,875 ProQR Therapeutics shares in Q4 2018, an estimated $1.02M.
Nexthera Capital first reported a position in ProQR Therapeutics in Q3 2018 and held it in 1 quarter.
Nexthera Capital's ProQR Therapeutics position peaked at $1.02M in Q3 2018.
57 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.